Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies — ScienceDaily By Dr. Brilliant | July 1, 2014 0 Comment source : http://www.sciencedaily.com/releases/2014/06/140628082340.htm